Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Avadel Pharmaceuticals plc’s stock clocked out at $14.92, up 0.40% from its previous closing price of $14.86. In other words, the price has increased by $0.40 from its previous closing price. On the day, 0.73 million shares were traded. AVDL stock price reached its highest trading level at $15.14 during the session, while it also had its lowest trading level at $14.445.
Ratios:
To gain a deeper understanding of AVDL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.52 and its Current Ratio is at 2.82. In the meantime, Its Debt-to-Equity ratio is 0.54 whereas as Long-Term Debt/Eq ratio is at 0.52.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on June 12, 2024, initiated with a Buy rating and assigned the stock a target price of $27.
On March 05, 2024, Oppenheimer reiterated its Outperform rating and also lowered its target price recommendation from $27 to $29.
Needham reiterated its Buy rating for the stock on March 05, 2024, while the target price for the stock was revised from $20 to $22.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 16 ’24 when MCHUGH THOMAS S bought 2,000 shares for $14.50 per share. The transaction valued at 29,000 led to the insider holds 80,500 shares of the business.
McCamish Mark Anthony sold 75,000 shares of AVDL for $1,089,750 on Dec 28 ’23. The Director now owns 67,025 shares after completing the transaction at $14.53 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVDL now has a Market Capitalization of 1436355840 and an Enterprise Value of 1402641280. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.10 while its Price-to-Book (P/B) ratio in mrq is 20.42. Its current Enterprise Value per Revenue stands at 14.742 whereas that against EBITDA is -14.426.
Stock Price History:
Over the past 52 weeks, AVDL has reached a high of $19.09, while it has fallen to a 52-week low of $10.25. The 50-Day Moving Average of the stock is 9.24%, while the 200-Day Moving Average is calculated to be -2.13%.
Shares Statistics:
It appears that AVDL traded 954.59K shares on average per day over the past three months and 1115640 shares per day over the past ten days. A total of 96.27M shares are outstanding, with a floating share count of 90.35M. Insiders hold about 6.15% of the company’s shares, while institutions hold 71.93% stake in the company. Shares short for AVDL as of 1728950400 were 10188890 with a Short Ratio of 10.67, compared to 1726185600 on 11661422. Therefore, it implies a Short% of Shares Outstanding of 10188890 and a Short% of Float of 12.100001.
Earnings Estimates
The market rating of Avadel Pharmaceuticals plc (AVDL) is currently shaped by the ongoing analysis conducted by 10.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.01, with high estimates of $0.05 and low estimates of -$0.05.
Analysts are recommending an EPS of between -$0.07 and -$0.59 for the fiscal current year, implying an average EPS of -$0.46. EPS for the following year is $0.68, with 9.0 analysts recommending between $1.64 and $0.26.
Revenue Estimates
In the current quarter, 9 analysts expect revenue to total $48.61M. It ranges from a high estimate of $50.32M to a low estimate of $47.1M. As of the current estimate, Avadel Pharmaceuticals plc’s year-ago sales were $7.01MFor the next quarter, 9 analysts are estimating revenue of $56.18M. There is a high estimate of $61.16M for the next quarter, whereas the lowest estimate is $51.61M.
A total of 9 analysts have provided revenue estimates for AVDL’s current fiscal year. The highest revenue estimate was $180.16M, while the lowest revenue estimate was $168.34M, resulting in an average revenue estimate of $173.6M. In the same quarter a year ago, actual revenue was $27.96MBased on 9 analysts’ estimates, the company’s revenue will be $300.47M in the next fiscal year. The high estimate is $333.51M and the low estimate is $280M.
